“2% fall in annual profit. It is really driven by declining revenue in its core plasma division... It's really facing a a temporary slowdown, due to a reduction in its US, inventory... it's certainly still facing plenty of headwinds.”
No settled horizons yet — outcomes appear at 30/90/365 days.